Of biopharma executives say they are not going back to a full traditional site-based development model

And they expect to use DCT even more

Of biopharma companies expect to conduct a clinical trial using DCT elements within the next year

But they’ll need help to activate & operationalize

Do not have the internal capabilities to operationalize any components of a decentralized clinical trial